Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Empagliflozin Tablets under Fasting Conditions
TCTR20250708004Phase 1Not yet recruiting
- Sponsor
- SciGen Ltd
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by SciGen Ltd. Primary endpoint: Primary pharmacokinetic bioequivalence parameters. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20250708004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250708004.